Amyotrophic lateral sclerosis is characterised by the progressive loss of motor neurons in
the brain and spinal cord. This neurodegenerative syndrome shares pathobiological …

Bulbar impairment represents a hallmark feature of Amyotrophic Lateral Sclerosis (ALS) that
significantly impacts survival and quality of life. Speech and swallowing dysfunction are key …

The identification of patient subgroups with differential treatment effects is the first step
towards individualised treatments. A current draft guideline by the EMA discusses potentials …

Amyotrophic lateral sclerosis is a devastating disease characterized primarily by motor
system degeneration, with clinical evidence of cognitive and behavioural change in up to …

Amyotrophic lateral sclerosis (ALS) therapeutic development has largely relied on staff-
administered functional rating scales to determine treatment efficacy. We sought to …

Introduction ALS functional rating scale (revised)(ALSFRS-R) is the most widely used
functional rating system in patients with amyotrophic lateral sclerosis (ALS). However …

Amyotrophic lateral sclerosis (ALS) exhibits characteristic variability of onset and rate of
disease progression, with inherent clinical heterogeneity making disease quantitation …

Prospective population based-registers of amyotrophic lateral sclerosis (ALS) have operated
in Europe for over two decades, and have provided important insights into our …

Amyotrophic lateral sclerosis is a progressive and devastating neurodegenerative disease.
Despite decades of clinical trials, effective disease-modifying drugs remain scarce. To …

The objective of present study was to assess the safety and efficacy of nanocurcumin as an
anti-inflammatory and antioxidant agent in adults with amyotrophic lateral sclerosis (ALS) …